Effect of surfactant replacement on Pneumocystis carinii pneumonia in rats by Eijking, E.P. (Eric) et al.
Intensive Care Med (1991) 17:475-478 
Intensive Care 
Medicine 
9 Springer-Verlag 1991 
Effect of surfactant replacement 
on Pneumocystis carinii pneumonia in rats 
E.P. Eijking ~, G.-J. van Daal 1, R. Tenbrinck ~, A. Luijendijk 2, J.F. Sluiters 2, E. Hannappel 3 
and B. Lachmann ~
Department of 1 Anesthesiology and 2 Clinical Microbiology, Erasmus University, Rotterdam, The Netherlands 
3 Institute of Biochemistry, University of Erlangen, Erlangen, FRG 
Received: 8 April 1991; accepted: 16 September 1991 
Abstract. The effect of intratracheal surfactant instilla- 
tion on pulmonary function in rats with Pneumocystis 
carinii pneumonia (PCP) was investigated. In those ani- 
mals which developed PCP with severe respiratory failure 
after administration of cortisone acetate s.c. over 8-12 
weeks, pulmonary function was improved by surfactant 
instillation. PaO 2 values 30 min after surfactant instilla- 
tion were significantly higher compared to pretreatment 
values and also compared to PaO2 values of rats 30 rain 
after receiving saline (482.9mmHg+_44.7, 170.7mmHg 
+ 39.3 and 67.2 mmHg+_ 17.4, respectively). Histological 
examination showed that alveoli of rats with PCP which 
received no exogenous urfactant are filled with foamy 
edema, whereas after exogenous urfactant alveoli are 
stabilized and well-aerated. These results indicate that ex- 
ogenous urfactant may help patients with severe PCP to 
overcome an acute stage of respiratory distress. 
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Animal model 
Infectious diseases are of great concern in intensive care 
health service in immunocompromized patients; especial- 
ly infectious diseases of the lung. In these patients 
Pneumocystis carinii is a major cause of pneumonia 
leading to severe respiratory distress [1, 21. It has been 
demonstrated in rats that Pneumocystis carinii pneumo- 
nia (PCP) decreases the total amount of phospholipids in
bronchoalveolar lavage (BAL) fluid whereas phospho- 
lipase activity in BAL fluid increases [3, 4]. Furthermore, 
lung compliance also decreases in PCP [3]. These find- 
ings suggest hat in the pathophysiology of respiratory 
failure in PCP the pulmonary surfactant system may be 
involved. 
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It has been repeatedly demonstrated by several au- 
thors that intratracheal instillation of exogenous surfac- 
tam restores lung function in animals with respiratory 
failure due to surfactant depletion or intratracheal HC1 
administration [5, 6]. Also large numbers of neonates 
with respiratory distress yndrome (RDS) due to lack of 
surfactant have been successfully treated with exogenous 
surfactant [7- 10]. 
We designed a study to investigate he effect of surfac- 
tant replacement therapy on pulmonary function in rats 
with PCP. If surfactant replacement would increase gas 
exchange, then one could conclude that a disturbed sur- 
factant system is one of the factors in the pathophysiolo- 
gy of respiratory failure in PCP. 
Materials and methods 
Surfactant 
The surfactant used in these experiments is a natural sur- 
factant isolated from bovine lungs in basically the same 
manner as described previously [11]. It consists of ap- 
proximately 83% phospholipids, 1% hydrophobic pro- 
teins (SP-B and SP-C), the remainder being other lipids 
such as cholesterol, glyceride and free fatty acids. There 
is no SPA in this surfactant preparation. 
Animal model 
This protocol was approved by the Animal Care and Use Committee of 
the Erasmus University Rotterdam, The Netherlands. 
The studies were performed in 28 male Wistar rats (initial body 
weight: 110-120 g), placed in two groups. The first group (n = 20) was 
treated with cortisone acetate, based on the model described by Frenkel 
and Chandler [12, 13]. These animals received 12.5 mg cortisone ace- 
tate, s.c. 4 times weekly over 8-12 weeks and 10 ixg/ml doxycycline in 
drinking water to reduce apossible bacterial superinfection. The second 
group (n = 8) received no treatment and served as controls. All animals 
were housed in standard plastic cages and received standard food ad 
libitum and were weighed at weekly intervals. 
After 8-12 weeks the cortisone acetate treated animals developed 
respiratory failure as judged by clinical symptoms (e. g. tachypnoea, 
cyanosis and fast decrease in body weight). Eleven animals died during 
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the night hours on various days before treatment with exogenous surfac- 
tant could be started. Nine rats which suffered clinically from respirato- 
ry failure were anesthetized with pentobarbital sodium (60 mg/kg, i.p.), 
tracheotomized and paralyzed with pancuronium bromide (0.5 mg/kg, 
i.m.). A catheter was inserted into the carotid artery for blood sam- 
pling. Animals were ventilated pressure-controlled with a Servo Ventila- 
tor 900 C (Siemens-Elema, Solna, Sweden) at the following settings: 
FiO 2 = 1.0, ventilation frequency = 30/min, peak airway pres- 
sure = 22 cm HzO, PEEP = 2 cm HzO and I : E = 1 : 2. 
After a_+20 rain stabilization period, 6 animals received bovine sur- 
factant (200 mg dry weight/kg body weight), suspended in 0.7 ml saline, 
intratracheally, whereas 3 received the same amount of saline. Blood 
samples were taken from the carotid artery immediately before surfac- 
tant instillation and at 30 and 60 rain post treatment. Blood gases were 
measured with the ABL 330 Acid-Base Laboratory (Radiometer, Co- 
penhagen, Denmark). 
Histological examination 
At the end of the experiments the animals were sacrificed with an over- 
dose of intra-arterially administered pentobarbital. The lungs were re- 
moved, the left lobe was minced and a cytospin preparation was made. 
This preparation was stained with a modified Gomori stain [141, which 
allows visualization of the cysts (not the intra-cystic structures) and 
Giemsa stain, and examined to confirm presence of PCR The right 
lobes were fixed in 10% formalin for light microscopy examination, de- 
hydrated, embedded in paraffin and 6 ~tm sections of the right middle 
lobe were stained with hematoxylin and eosin, Grocott-Gomori 
methenamine silver nitrate and periodic acid-Schiff stain. 
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Fig. 1. PaO 2 values of the different groups before treatment ("Before") 
and 30rain and 60min after treatment (respectively: "30rain" and 
"60rain"). Grey bar = healthy controls; striped bar = saline group; 
open bar = exogenous surfactant group. (*= significantly different 
from pre-treatment; ** = significantly different from surfactant treated 
rats (p < 0.05)) 
In all 9 lung homogenates a large amount  of cysts was 
present which confirmed the presence of PCP in all ani- 
mals. 
Statistical analysis 
statistical evaluation ofdata was performed using the Wilcoxon signed 
rank test for paired observations or the Mann-Whitney-U test (two-tail- 
ed). All data are expressed asmean_+SEM. Statistical significance was 
accepted at p < 0.05 (two-tailed). 
Results 
Blood gases 
During an 8 -12  weeks period the animals developed re- 
spiratory insufficiency which could be reversed by surfac- 
tant instil lation. PaO2 values at 30 and 60 min after sur- 
factant instil lation are significantly higher compared to 
pre-treatment values. There was no significant difference 
between PaO2 values after surfactant reatment and 
PaO2 values of healthy control animals, though the latter 
were somewhat higher. Intratracheal insti l lation of only 
saline, however, led to a decrease of PaO2 compared to 
pre-treatment PaO 2 values. The difference at 30 and 
60 rain between rats receiving surfactant and rats receiv- 
ing saline is significant. Pre-treatment PaO2 values of 
both groups do not differ significantly (Fig. 1). Figure 2 
shows one example of a dramatic increase of PaO 2 of a 
rat with PCP treated with exogenous surfactant. This rat 
had the lowest PaO 2 of the whole group. 
Histological findings 
Histological examination of lungs of rats with PCP 
which received only saline and no exogenous urfactant 
showed alveoli filled with a characteristic foamy edema 
(Fig. 3). Surfactant reatment resulted in stabilized and 
aerated alveoli, thus allowing the emphysematous struc- 
ture of the lungs to become apparent (Fig. 4). 
Discussion 
The treatment of choice in patients uffering from respi- 
ratory failure due to PCP is administrat ion of an- 
timicrobial drugs combined with ventilatory support. The 
aim of the present study was to investigate the effect of 
an exogenous surfactant preparation on gas exchange un- 
der unchanged ventilator settings in an animal model of 
PCP. 
The pr imary functions of surfactant are stabilization 
of alveoli of different size at end expiration and reduction 
of work of breathing by reducing surface tension at the 
air-l iquid interphase on the alveolar walls [15]. In this 
study two hypotheses were proven valid: hypothesis 1) if 
surfactant is necessary to keep retractive forces as low as 
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Fig. 2. PaO 2 over time in a rat with PCP having the lowest PaO 2 of the 
whole group before surfactant treatment: inthis animal PaO a was also 
measured i0 rain after surfactant instillation. The arrow indicates the 
time of surfactant instillation 
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Fig. 3. Typical histological findings in a rat with PCP which received sa- 
line instead of exogenous surfactant. Hematoxylin and eosin stain; the 
scale-line quals 100 grn 
possible and to ensure optimal gas exchange, any distur- 
bance in the surfactant system will result in abnormalities 
in lung distensibility and gas exchange; hypothesis 2) if 
the first hypothesis  correct, surfactant replacement will 
restore lung distensibility and gas exchange to normal. In 
other words, if surfactant replacement improves de- 
creased lung compliance and impaired gas exchange in 
lung diseases of different etiologies, then the surfactant 
system is also involved in the pathogenesis of these lung 
diseases [161. 
The results of this study demonstrate that surfactant 
instillation in rats with respiratory failure due to Pneu- 
mocystis carinii infection leads to restoration of pulmo- 
nary gas exchange, which could be demonstrated byim- 
provement of blood gases and by histological examina- 
tion. These results underline our hypothesis that the pul- 
monary surfactant system isat least partly responsible for 
the respiratory failure caused by PCP. The mechanism 
can be explained as follows: as a result of damage to the 
alveolar-capillary membrane caused by infection with 
Pneumocystis carinii, large volumes of edema fluid accu- 
Fig. 4. Typical histological findings in rats with PCP after treatment 
with surfactant; note the emphysematous structure. Hematoxylin and 
eosin stain; the scale-line quais 100 gm 
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mulate into the alveolar space. This edema contains large 
amounts of plasma proteins and specific enzymes capa- 
ble of disrupting the surfactant system [3, 4, 17-19]. As 
a result of this functional surfactant deficit, surface ten- 
sion at the airliquid interphase on the alveolar wall in- 
creases, leading to increased retractive force across the al- 
veolar-capillary membrane, with subsequent formation 
of atelectatic areas, functionally expressed as a decrease 
in functional residual capacity (FRC). This leads to a 
mismatch of the ventilation-perfusion ratio resulting in 
hypoxemia. Also, due to increase of surface tension on 
the alveolar walls, suction force across the alveolar-capil- 
lary membrane increases, facilitating a further outpour- 
ing of edema [20]. The mechanism by which surfactant 
replacement therapy leads to improvement of gas ex- 
change can be explained by reversing these mechanisms. 
The fact that gas exchange improves only after adminis- 
tration of surfactant and ot after saline indicates that 
the positive effect observed is caused by surfactant and 
not by the fluid itself. 
In all animals treated with exogenous surfactant it was 
also found that many alveolar septa were damaged, lead- 
ing to an emphysematous l ng structure. Similar observa- 
tions were reported recently in patients with PCP [21]. 
These findings uggest that in PCP lungs proteolytic en- 
zymes may be over-represented. These proteolytic en- 
zymes are perhaps excreted by activated leukocytes at- 
tracted to the site of inflammation. Also in the past it has 
been found that type I pneumocytes undergo degenera- 
tive changes in rats infected with Pneumocystis carinii. 
This leads to damage to the ultrastructure of the alveolar 
wall, thus leading to increased permeability of the alveo- 
lar-capillary membrane [22]. Perhaps both mechanisms 
play a role in the damage of the alveolar septa. It could 
be speculated that proteinase inhibitors, given to the pa- 
tient after manifestation of pneumocystis carinii infec- 
tion, could prevent (further) morphological damage to 
the pulmonary structure. 
It is established that immunosuppressed rats, as is the 
case in humans, can develop Pneumocystis carinii infec- 
tion of the lungs, leading to respiratory distress. The cur- 
rent treatment of choice is parenteral dministration f
trimethoprim-sulfamethoxazole or p ntamidine-isothio- 
note. Both drugs have about the same rate of success of 
around 75~ (percentages vary depending on the study) 
but high incidences of systemic adverse reactions are re- 
ported (for review see [23]). To prevent these adverse reac- 
tions it is necessary to lower the systemic oncentration, 
which led to studies on aerosolized pentamidine. Results 
from these aerosol studies have shown that it is possible 
to get high concentrations i  the lungs with low systemic 
concentrations [24, 25]. For the future one could specu- 
late to use surfactant as a carrier-substance for an- 
timicrobial drugs, this way achieving high intra-alveolar 
drug concentration a d low systemic oncentration. 
In conclusion, it has been demonstrated that surfac- 
tant instillation can improve gas exchange in rats suffer- 
ing from respiratory failure due to PCE These results 
could be important in future for treatment regimens of 
patients uffering from acute respiratory failure due to 
PCR 
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